Business Context and Reporting Period
Company: Evotec SE (Evotec Aktiengesellschaft)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2009
Accounting Standards: International Financial Reporting Standards (IFRS)
Reporting Currency: Euro (EUR)
Evotec is a drug discovery and development company providing integrated services and alliances to the pharmaceutical and biotechnology industries. The company operates primarily in Germany, the UK, the US, and India. In 2009, the company executed a strategic restructuring ("Evotec 2012") to focus on high-value discovery alliances and core proprietary programs, resulting in the wind-down of its US operations at Renovis, Inc. and the acquisition of a 70% stake in Research Support International Private Limited (RSIPL) in India.
Key Financial Metrics
| Metric (EUR thousands) | 2009 | 2008 |
|---|---|---|
| Revenue (Continuing Operations) | 42,683 | 39,613 |
| Operating Loss | (42,299) | (73,210) |
| Net Loss | (45,497) | (78,287) |
| Net Loss Per Share (Basic/Diluted) | (0.43) | (0.82) |
| Cash and Cash Equivalents (Year End) | 32,926 | 55,064 |
| Total Assets | 146,599 | 182,900 |
| Long-Term Debt | 3,889 | 8,393 |
| Stockholders' Equity | 111,487 | 149,859 |
| Net Cash Used in Operating Activities | (21,853) | (41,278) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 8% to €42.7 million, driven by strong performance in discovery alliances, the out-licensing of the EVT 100 compound family to Roche, and revenues from the newly acquired RSIPL business. This offset a decrease in milestone payments from Boehringer Ingelheim (€4.0 million in 2009 vs. €8.5 million in 2008).
- Significant Loss Reduction: The operating loss improved by 42% to €42.3 million. This was primarily due to a 51% reduction in Research and Development (R&D) expenses (€20.9 million vs. €42.5 million) and lower impairment charges compared to 2008, partially offset by €4.8 million in restructuring expenses.
- Impairment Charges: The company recognized €18.2 million in non-cash impairment of intangible assets in 2009, primarily related to the VR1 program (€6.6 million), EVT 401 (€6.8 million), and EVT 201 (€4.4 million). This was a reduction from the €27.6 million in total impairments (goodwill and intangibles) recorded in 2008.
- Restructuring: Implementation of the "Evotec 2012" plan resulted in €4.8 million in restructuring costs, including the closure of the Renovis site in South San Francisco and personnel reductions in Germany and the UK.
- Liquidity: Cash and cash equivalents decreased by approximately €22.1 million to €32.9 million, reflecting net cash used in operating activities and investing activities (including the RSIPL acquisition), despite a reduction in operating cash burn.
Guidance, Outlook, and Risks
- Outlook: Management expects revenues before out-licensing income to increase by at least 15% in 2010. R&D expenses are projected to decrease to below €10.0 million in 2010 due to the focus on key assets and Roche funding clinical expenses for EVT 101 and EVT 103. The company expects to be profitable by 2012.
- Liquidity Position: Based on current plans, existing cash, investments, and operating revenues are sufficient to fund planned activities beyond 2012. The company expects to end 2010 with liquidity exceeding €60 million (excluding M&A outflows).
- Key Risks:
- Clinical Trial Failures: EVT 302 failed a Phase II study for smoking cessation in 2009, leading to a cessation of internal investment. EVT 201 (insomnia) has not been partnered and requires a partner for Phase III.
- Partner Dependence: The company relies on strategic partners (e.g., Roche, Boehringer Ingelheim, Pfizer) for revenue and development. In 2009, the largest single customer accounted for 21.3% of total revenues.
- Intellectual Property: Significant reliance on licensed IP from third parties, including Roche. Termination of these licenses could harm the business.
- Market Conditions: Pricing pressures from biotechnology customers and competition from low-cost countries pose risks to margins.
- Unusual Items: The company voluntarily delisted its ADSs from NASDAQ on November 30, 2009; they now trade on the over-the-counter market. The company also recorded a foreign exchange loss of €1.6 million related to the repayment of share capital of a UK subsidiary.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the €32.9 million cash balance against the projected €10 million R&D spend and operating costs for 2010-2012.
- Roche Partnership: Confirm the status of the Phase II trial for EVT 101 (treatment-resistant depression) scheduled to start in June 2010, as this is critical for potential €65 million buy-back payments.
- Impairment Reversals: Review the €0.4 million reversal of impairment on property, plant, and equipment to ensure asset utilization assumptions are realistic.
- Customer Concentration: Assess the risk associated with the top two customers representing over 40% of group revenues in 2009.
- ADS Liquidity: Evaluate the impact of the NASDAQ delisting on the liquidity and trading volume of American Depositary Shares (ADSs).